SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 2020 Italy English Publisher:WileyJournal:Journal of the European Academy of Dermatology and Venereology, volume 34 (issn: 0926-9959, eissn: 1468-3083,

Copyright policy )

Authors: Messina, F.; Piaserico, S.;

doi: 10.1111/jdv.16468

handle: 11577/3339849

SARS‐CoV‐2 infection in a psoriatic patient treated with IL‐23 inhibitor

- Summary
- Subjects
- Metrics

Abstract

Since December 2019, an outbreak of 2019 novel coronavirus disease (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been spreading worldwide. This has risen concern among patients undergoing biologics and physicians who administer them, as far as the possible increase of incidence and severity of COVID‐19 in this delicate population concerns.

Country

Italy

Related Organizations

University of Padua
Italy

Keywords

Infectious Diseases, Dermatology, biologic; covid-19; guselkumab; psoriasis; SARS-CoV-2

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	54
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%